PONVORY™ (ponesimod)

PONVORY™ WAS PROVEN SUPERIOR AT REDUCING RELAPSES* AND LESIONS VS AUBAGIO® IN A STUDY LASTING ~2 YEARS

PONVORY™

 

Proven to help control the symptoms and signs of relapsing MS in adults

SUPERIOR at reducing relapses* and the number of new and enlarging lesions vs a proven oral therapy (Aubagio®)

Unlike an injection or infusion, PONVORY™ is an oral, once-daily pill that is discreet and can be taken anywhere. Most people can take their first dose at home

*PONVORY™ was shown to reduce the average number of relapses per year.

PONVORY™ was shown to reduce the average number of new gadolinium-enhancing (GdE) T1 and new or enlarging T2 lesions.

Most people take their first dose of PONVORY™ at home, but first-dose monitoring is required for people with certain cardiac conditions (slow heart rate, certain types of heart block, and heart attack or heart failure occurring >6 months prior to treatment initiation and in stable condition). Supervision of this first dose should take place in a healthcare setting.

relapsing-ms

Approved by the FDA for relapsing MS

 

PONVORY™ is part of a group of MS medicines called disease-modifying therapies (DMTs).

conversation

Get the conversation started

 

Explore resources that can help you talk to your healthcare professional about PONVORY™.

ponvory treatment
getting-started

Ready to begin your treatment journey with PONVORY™?

 

See what’s ahead.

Explore available savings options

 

Interested in cost support?

Your story could help others

Your story could help others